Rules-Based Medicine

(+01) 512 835 8026

Email us

Type your search term and press "enter."



Interleukin-13 (IL-13)

Ultrasensitive Immunoassay


Rules-Based Medicine’s internally developed and manufactured ultrasensitive immunoassay to interleukin-13 (IL-13) based on the Simoa® bead technology can accurately quantitate sub-pg/mL levels of IL-13 in serum or plasma. Such sensitive IL-13 physiological detection empowers clinical researchers in areas of allergic inflammation, asthma, and fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).

IL-13 is a 13kD protein secreted primarily by T helper type 2 (Th2) cells and natural killer cells, mast cells, basophils, and eosinophils. IL-13 plays a central role in the Th2 response and shares many biological activities with IL-4, as they share a common receptor subunit (α subunit). IL-13 receptors (IL-4Rα and two IL-13 binding proteins, IL-13Rα1 and IL-13Rα2) are expressed on human B cells, basophils, eosinophils, mast cells, endothelial cells, fibroblasts, monocytes, macrophages, respiratory epithelial cells, and smooth muscle cells. The primary functions of IL-13 is to regulate inflammation, mucus production, tissue remodeling, and fibrosis. IL-13 is also essential for host protection against helminth infections.

IL-13 is an important therapeutic target for several diseases, including asthma, fibrosis, ulcerative colitis, and other inflammatory diseases in which IL-13 is overproduced. Overproduction of IL-13 drives airway inflammation and bronchial obstruction, a pathogenesis of asthma. IL-13 driven eosinophilic disorder plays a role in atopic dermatitis, eosinophilic esophagitis, and other chronic inflammatory intestinal diseases. IPF patients have elevated levels of IL-13 in the bronchoalveolar lavage fluid, and those with rapid progressive disease have enhanced pathway activation of IL-13. Anti-IL-13 therapy (tralokinumab, lebrikizumab) is being actively investigated in asthma, allergic inflammatory diseases, and IPF. Myriad RBM’s Simoa IL-13 ultrasensitive assay can be an essential clinical research partner for monitoring IL-13.


Swiss-Prot Accession Number: P35225

Alternate names for this biomarker include:


Simoa™ Services
Biomarker LLOQ*
(Serum and Plasma)
(Undiluted Samples)
Volume Required
Serum or plasma Other fluids**
Interleukin-13 (IL-13) 0.099 pg/mL 0.0495 pg/mL 150 µL 150 µL

* Lower limit of quantitation (LLOQ) represents the lowest amount of an analyte that can be quantitatively determined with acceptable precision. LLOQ is determined by performing 2-fold serial dilutions of Standard to be tested in triplicate over three runs. The percent coefficient of variation (CV) is calculated for each of the dilution replicates, and the LLOQ is determined as the concentration at which the CV is 30%.

** Cerebrospinal fluid, urine, tissue culture supernatants,  bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.

All assay services are performed in our CLIA-certified laboratory.
Intended for Research Use Only.